Four plenary discussions are planned for SIO’s 2017 international conference on November 12-14 in Chicago. Topics will be Natural Products and Diet on Microbiome and Cancer; Meeting the Integrative Oncology Needs of Young Adult Cancer Patients; Integrative Innovations in Digital Health Technologies with Cancer Patients and Survivors and Art as Medicine.

In newly updated clinical guidelines from SIO, researchers at Columbia University’s Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center with an interdisciplinary team of colleagues at MD Anderson Cancer Center, University of Michigan, Memorial Sloan Kettering Cancer Center, and other institutions in the U.S. and Canada, analyzed which integrative treatments are most effective and safe for patients with breast cancer. This systematic review adds to the growing literature on integrative therapies for patients with breast cancer and other cancer populations. The latest results are published online and in print in CA: A Cancer Journal for Cliniciansa publication of the American Cancer Society. 

Coriolus versicolorCoriolus versicolor (or Trametes versicolor), a medicinal mushroom, was chosen for this month’s issue because it is employed as an adjuvant agent in the treatment of cancer. It is popularly known as the “turkey tail mushroom” because of its resemblance to the multi-colored tail of a wild turkey.

We chose astragalus, an herb widely used in Traditional Chinese Medicine, for this month because of its popularity as an immunostimulant.